Expert Highlights Caution for Chemo Substitutions for Gynecologic Cancers

Commentary
Video

Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.

Brian Slomovitz, MD, MS, FACOG, spoke with CancerNetwork® about the potential impact of substituting platinum-based chemotherapy for other platinum-based agents in the treatment of those with gynecologic cancers during the ongoing chemotherapy shortage in the United States.

Slomovitz, a gynecologic oncologist, director of Gynecologic Oncology, and co-chair of the Cancer Research Committee at Mount Sinai Medical Center in Miami Beach, Florida and a professor of Obstetrics and Gynecology at Florida International University, emphasized caution when making the decision to switch from carboplatin to cisplatin, or vice versa, as it is unclear how the change may impact patient outcomes or quality of life. He did note that the substitution does make sense in theory, but also stated it’s important to remember that they’re different agents.

Additionally, he spoke about how guidelines from organizations such as the Society of Gynecologic Oncology (SGO) may help in guiding treatment decision-making during the platinum-based chemotherapy shortages.

Transcript:

The quality of life definitely [is impacted] for a lot of perspectives, because the [adverse] effect profiles can be different and things like that. We've had to make some changes. We've written some consensus pieces on that, part of it with the Society of Gynecologic Oncology [SGO], which are nice guides of what to do in the setting. But there is some unknown. When we've studied thousands of patients for certain diseases like ovarian cancer with carboplatin, and then we say, ‘Hey, let's switch. Let's give cisplatin.’ Theoretically, it makes sense. But the bottom line is they're different drugs. I don't want to say to keep our fingers crossed; it's a little bit more scientific than that. But we're cautious that the efficacy is going to be the same.

Reference

SGO statement: carboplatin and cisplatin shortages. News release. Society of Gynecologic Oncology. April 21, 2023. Accessed August 7, 2023. https://tinyurl.com/y3dcmdk4

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content